Nanexa’s product project NEX-18 aims to drive the development of a PharmaShell® coated drug product targeting two forms of aggressive leukemia – Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Nanexa drives NEX-18 through the first phases of clinical testing.

Myelodysplastic syndrome (MDS), is a group of chronic diseases where normal blood formation does not function normally. The reason for this is that the blood-forming stem cells in the bone marrow are unable to produce mature blood cells of different types (red and white blood cells and platelets). In most cases, this causes anemia, a too low white blood cell count (leukopenia) and a reduced platelet count (thrombocytopenia) in patients. In some other cases, however, the disease may initially resemble a chronic leukemia with an increased number of white blood cells in the blood.

Acute myeloid leukemia (AML), also referred to as acute myeloblast or myeloid leukemia, is one of the most common forms of adult leukemia. The diagnosis is based on the finding of abnormal cells in the blood and bone marrow with a concomitant decrease in the number of normal red and white blood cells and platelets. In contrast to acute lymphocytic leukemia (ALL), the mature blood cells do not constitute lymphoblasts but are precursors in the formation of white blood cells, red blood cells and/or platelets. About 30,000 people suffer from AML per year in the US and Europe.

Azacitidine with PharmaShell®

Our assessment is that a simplified treatment with one subcutaneous injection that replaces the seven injections needed with today’s azacitidine formulation will fill a great need for both healthcare and patients.


“The product improvement that NEX-18 represents will be very significant both for patients in the form of less need for traveling to and from hospitals, as well as providing opportunities for major savings in healthcare in terms of both time and money.”

Blood Cancer Specialist, Rochester, USA